



Sigilon Therapeutics Announces Presentations at the American Society of Gene and Cell Therapy 24th Annual Meeting

April 27, 2021

Presentations include initial results from preclinical studies of expanded pipeline programs in immune-mediated and metabolic diseases

CAMBRIDGE, Mass., April 27, 2021 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today announced that four abstracts were selected for presentation at the American Society of Gene and Cell Therapy (ASGCT) 24th Annual Meeting, which will take place virtually from May 11-14, 2021. Among the presentations, are initial results from the study of Sigilon's novel Shielded Living Therapeutics™ (SLTx) technology in animal models of immune-mediated hepatitis and hypoparathyroidism, which reflects the modularity and expansion of Sigilon's pipeline programs. Overall, SLTx demonstrated the potential to overcome limitations associated with current therapies for these immune-mediated and metabolic disorders.

The presentations will be made available on the ASGCT website starting on May 11th, 2021 at 8:00 AM EDT. The posters will also be made available in the Publications section of Sigilon's corporate website following the presentations.

POSTER PRESENTATION DETAILS

Title: "A Scaled and Semi-Automated Cell Encapsulation Process for a Shielded Cell-Based Platform for Chronic Diseases"

Abstract Number: 865

Session: 531 – Cell Therapy Product Engineering, Development or Manufacturing

Title: "Continuous Delivery of IL-10 Using the Shielded Living Therapeutics™ Platform Leads to Modulation of Immune Cell Function and Prevents Liver Damage in Preclinical Model of Immune-Mediated Hepatitis"

Abstract Number: 704

Session: 523 – Hematologic and Immunologic Diseases

Title: "Tunable Delivery of Parathyroid Hormone with the Shielded Living Therapeutics™ Platform Provides a New Modality for Treatment of Hypoparathyroidism"

Abstract Number: 510

Session: 512 – Metabolic, Storage, Endocrine, Liver and Gastrointestinal Disease

Title: "Analytical Development Considerations for the Shielded Living Therapeutics™ Platform: A Novel Encapsulated Cell-Based, Non-Viral Platform for Delivery of Therapeutic Proteins"

Abstract Number: 864

Session: 531 – Cell Therapy Product Engineering, Development or Manufacturing

About Sigilon Therapeutics

Sigilon Therapeutics seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform. Sigilon's product candidates are non-viral engineered cell-based therapies designed to produce the crucial proteins, enzymes or factors needed by patients living with chronic diseases such as hemophilia, lysosomal disorders and diabetes. The engineered cells are protected by Sigilon's Afibromer™ biomaterials matrix, which shields them from immune rejection and fibrosis. Sigilon was founded by Flagship Pioneering in conjunction with Daniel Anderson, Ph.D., and Robert Langer, Sc.D., of the Massachusetts Institute of Technology.

Forward-Looking Statements

This press release includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as "anticipate," "expect," "plan," "could," "may," "will," "believe," "estimate," "forecast," "goal," "project," and other words of similar meaning. These forward-looking statements address various matters, including the modularity of our pipeline programs and our ability to overcome limitations associated with current therapies for immune-mediated and metabolic disorders. Each forward-looking statement contained in this press release is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others, those related to our clinical and preclinical research, product candidates and the regulatory filings related thereto, and the risks identified under the heading "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2020, and filed with the Securities and Exchange Commission, as well as the other information we file with the SEC. We caution investors not to place considerable reliance on the forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at www.sec.gov, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document, and we undertake no obligation to update or revise any of these statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.

SOURCE: Sigilon Therapeutics, Inc.

Investor Contacts

Glenn Reicin
Sigilon Therapeutics, Chief Financial Officer
glenn.reicin@sigilon.com
646-696-4344

Jennifer Porcelli
Solebury Trout
jporcelli@soleburytrout.com
646-378-2962

Media Contact

Amy Bonanno
Solebury Trout
abonanno@soleburytrout.com
914-450-0349